EU allocates 54.4B euros for FP7

4 June 2006

At its end-May meeting, the Council of the European Union reached agreement on a general approach on the Seventh Framework Program (FP7) for research and technological development (Marketletters passim), pending the European Parliament's opinion.

Following the inter-institutional agreement on the EU's budget for 2007-13, a total of 54.5 billion euros ($69.5 billion) will be allocated for the FP7. This is organized in four specific programs, corresponding to four major objectives of European research policy, as follows:

- cooperation: on collaborative research, with more than 32.0 billion euros allocated; - ideas: which includes the establishment of a European Research Council that would receive s total of 7.5 billion euros' - capacities: dealing with potential research capacities of the EU's small and medium-sized enterprises, with approximately 4.2 billion euros; and - people: for human resources, receiving around 5.0 billion euros.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight